Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery.

about

Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery.

Item

http://www.wikidata.org/entity/Q35870134

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Immune checkpoints: Cytotoxic ...... in 1 in breast cancer surgery.

@ast

Immune checkpoints: Cytotoxic ...... in 1 in breast cancer surgery.

@en

type

Item

label

Immune checkpoints: Cytotoxic ...... in 1 in breast cancer surgery.

@ast

Immune checkpoints: Cytotoxic ...... in 1 in breast cancer surgery.

@en

prefLabel

Immune checkpoints: Cytotoxic ...... in 1 in breast cancer surgery.

@ast

Immune checkpoints: Cytotoxic ...... in 1 in breast cancer surgery.

@en

P1476

Immune checkpoints: Cytotoxic ...... in 1 in breast cancer surgery.

@en

P2093

Agnieszka Kolacinska

http://www.w3.org/2001/XMLSchema#string

Alina Morawiec-Sztandera

http://www.w3.org/2001/XMLSchema#string

Dorota Jesionek-Kupnicka

http://www.w3.org/2001/XMLSchema#string

Izabela Zawlik

http://www.w3.org/2001/XMLSchema#string

Justyna Chalubinska-Fendler

http://www.w3.org/2001/XMLSchema#string

Lukasz Pakula

http://www.w3.org/2001/XMLSchema#string

Piotr Smolewski

http://www.w3.org/2001/XMLSchema#string

Zbigniew Morawiec

http://www.w3.org/2001/XMLSchema#string

Zofia Pawlowska

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

A systems biology approach to the effect of aging, immunosenescence and vaccine response

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Nivolumab plus ipilimumab in advanced melanoma.

The blockade of immune checkpoints in cancer immunotherapy

Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

P304

1079-1086

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2015.3321

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Barbara Cebula-Obrzut

P577

2015-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281400495

http://www.w3.org/2001/XMLSchema#string

P698

26622629

http://www.w3.org/2001/XMLSchema#string

P932

4508983

http://www.w3.org/2001/XMLSchema#string